Clinical trials
Neuromyelitis Optica clinical trials
Below are recruiting neuromyelitis optica clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05549258RecruitingPhase 2
Inebilizumab for children with NMOSD who had recent relapses
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
La Jolla, CaliforniaAges 2–17 - NCT05891379Recruiting
Inebilizumab for adults with acute neuromyelitis optica attacks
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06398158Recruiting
Ravulizumab and its impact on neuromyelitis optica
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
Dallas, TexasAges 18 years+ - NCT06620809RecruitingPhase 1
Safety and efficacy of NouvSoma001 for NMOSD
This trial tests a new treatment called NouvSoma001 for neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the optic nerves and spinal cord. It looks at whether the drug is safe and helps people who have had a recent attack with severe pain, trouble walking, or bladder/bowel problems.
Wuhan, HubeiAges 18–65 - NCT06374264Enrolling by invitation
Music-based walking therapy for NMOSD
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
Atlanta, GeorgiaAges 18–70 - NCT06763848Recruiting
Blood filtering for NMOSD attacks
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
Guangzhou, GuangdongAges 18–65 - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80 - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT06413654RecruitingPhase 2/Phase 3
B001 for NMOSD: reducing relapses
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
BeijingAges 18 years+ - NCT04886492Enrolling by invitation
NMOSD patient registry to help study future treatments
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
Waltham, MassachusettsAges 18 years+ - NCT05909761Recruiting
Pregnancy Uplizna safety study in women with NMOSD
This is an observational study that looks at the safety of Uplizna (satralizumab) during pregnancy for women who have neuromyelitis optica spectrum disorder (NMOSD). You may be asked to share information because your exposure to Uplizna happened during pregnancy or just before conception.
Aurora, ColoradoAges 15 years+ - NCT06865274Recruiting
A look at gene changes in MS, NMOSD, and MOGAD
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
Roma, RomaAges 18 years+ - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT07762872Recruiting
Satralizumab during early NMOSD attacks
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT05017142Recruiting
Pediatric brain inflammation registry for Swiss patients
This study is a registry that collects health information from children and teens in Switzerland diagnosed with certain inflammatory brain and spinal cord conditions. It helps researchers understand these illnesses better over time and may guide future treatments.
Aarau, Canton of AargauAges Up to 36 years - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05504694RecruitingPhase 1/Phase 2
Ofatumumab for AQP4-positive NMOSD with recent relapses
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
Xi'an, ShaanxiAges 18 years+ - NCT05566769Recruiting
Test a phone tool for self-checks in NMOSD
This study tests a digital (phone) tool that helps people with NMOSD do unsupervised self-assessments between clinic visits. It looks at how well the tool works and whether it is safe and understandable for patients.
Los Angeles, CaliforniaAges 18 years+ - NCT05966467Recruiting
Patient registry for AQP4+ neuromyelitis optica on C5 inhibitors
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05982925Recruiting
Brain imaging study in multiple sclerosis
This study uses MRI scans to look at how multiple sclerosis affects the outer layer of the brain over time. It aims to learn more about the disease to help improve future treatments.
New York, New YorkAges 18 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuromyelitis optica?
- Yes. Clin2 currently lists 37 recruiting neuromyelitis optica studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuromyelitis optica trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuromyelitis optica trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.